GeoVax Labs, Inc., a clinical-stage biotechnology company, will present its research at the 37th Annual Roth Conference in Dana Point, California. Chairman and CEO David Dodd is scheduled to participate in a fireside chat on March 17, 2025, discussing the company's work in vaccine development and cancer therapies. The company's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine undergoing multiple Phase 2 clinical trials. These trials are exploring the vaccine's potential in critical patient populations, including immunocompromised individuals, patients with chronic lymphocytic leukemia, and as a booster for those previously vaccinated with mRNA vaccines.
Recently awarded a BARDA-funded contract, GeoVax will sponsor a comprehensive 10,000-participant Phase 2b clinical trial to evaluate GEO-CM04S1's efficacy compared to existing COVID-19 vaccines. This research aims to address limitations in current vaccine technologies, particularly for patients with complex medical conditions. The implications of this work are significant as it could provide better protection for vulnerable populations who may not respond adequately to current vaccines. The company's approach represents an important step in developing more effective solutions for ongoing public health challenges.
In oncology, GeoVax is advancing Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy. Having completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, the company plans a Phase 2 clinical trial exploring Gedeptin® in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer patients. This combination approach could potentially improve outcomes for patients with limited treatment options. The development of novel cancer therapies like Gedeptin® addresses the ongoing need for more effective treatments for solid tumors, which remain challenging to treat with conventional approaches.
The company's robust intellectual property portfolio and experienced leadership team position GeoVax at the forefront of developing transformative medical technologies targeting some of the world's most challenging infectious diseases and cancer treatments. The presentation at the Roth Conference provides an opportunity to showcase these advancements to the investment community and highlight the company's progress in addressing significant unmet medical needs. The research presented has implications for both public health preparedness and cancer treatment paradigms, representing important developments in medical science that could benefit patients worldwide.
